KMT2A and leukemia: As the first proof-of-concept for targeting the DPY30-ASH2L interaction, a peptide derived from ASH2LDBM (residues 510-529) decreased the global H3K4me3 and modestly inhibited the growth of MLL-rearranged leukemia (Shah et al., 2019), demonstrating the feasibility of targeting the DPY30-ASH2L interaction for cancer treatment.